Zbiotics has sold 8m bottles of its flagship product, a shot containing bacteria that express an enzyme that breaks down alcohol in the gut.

Since launching in late 2023, Doctronic has provided 10 million quick, free and private medical consultations.

Absci entered its new drug into Phase I trials in half the time and for many millions of dollars less than it would have cost ...

Azafaros has secured 132 million euros ($147 million) in series B funds that the Dutch biotech will use to push its rare ...

Azafaros raises $146M Series B to advance nizubaglustat into Phase 3 trials for rare lysosomal storage disorders, with ...

Bactana Corp., a biotech startup headquartered at UConn’s Technology Incubation Program in Farmington, announced Tuesday it ...

The founder and former leader of Inhibikase Therapeutics is blazing a new biotech trail in an effort to get a beleaguered ...

A combination of the HER2 agent, called disitamab vedotin, and Junshi Biosciences’ PD-1 inhibitor toripalimab outperformed ...

Arrepath Inc. has patented new UDP-2,3-diacylglucosamine hydrolase (LpxH) (bacterial) inhibitors reported to be useful for the treatment of gram-negative bacterial infections.

New research has revealed the potential of engineered proteins to more precisely deliver drugs within the body.

Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...